NEUROSCREEN - Sensitive and differential blood and cerebrospinal fluid test for neurodegenerative dementia diagnosis (FP6-LIFESCIHEALTH) (2007-01-01 - 2009-12-31) (»add to infobox)

Willy ZORZI, Gilbert LEGEAY, Jean-Philippe DESCOMBES, Jean-François DELFORGE, Awad OSMAN, Fabienne PONCIN-EPAILLARD, Armand PERRET-LIAUDET, Marc RODRIGUE, Miran MOZETIC, David ALLSOP, Gabor Geza KOVACS, Andreas KAGE

UNIVERSITE DE LIEGE (BE332 - Arr. Liège) (Belgium), ASSOCIATION POUR LES TRANSFERTS DE TECHNOLOGIE DU MANS (FR514 - Sarthe) (France), EUDICA SA (FR718 - Haute-Savoie) (France), ALCIS (FR431 - Doubs) (France), AJ ROBOSCREEN GMBH (DED31 - Leipzig, Kreisfreie Stadt) (Germany), UNIVERSITE DU MAINE (FR514 - Sarthe) (France), HOSPICES CIVILS DE LYON (FR716 - Rhône) (France), BIOMERIEUX SA (FR716 - Rhône) (France), INSTITUT JOZEF STEFAN (SI00E - Osrednjeslovenska) (Slovenia), LANCASTER UNIVERSITY (UKD43 - Lancashire CC) (Great Britain), ORSZAGOS PSZICHIATRIAI ES NEUROLOGIAI INTEZET (HU101 - Budapest) (Hungary), CHARITE - UNIVERSITAETSMEDIZIN BERLIN (DE300 - Berlin) (Germany)

The project aims to develop an integrated system allowing differential diagnosis of neurodegenerative diseases based on several patented, sensitive and robust technologies. This system uses an ultrasensitive detection of specific direct and indirect amyloid-related markers in the cerebrospinal fluid and in blood, with new derivative products of nano/micro biosciences. Among diseases with amyloid deposits, the NeuroScreen project will focus on Alzheimer and Prion diseases for which some ambiguities still exist regarding their differential diagnosis. At present, their diagnosis must be confirmed by post-mortem cerebral analysis. The experimental work is broken into 7 workpackages management being gathered in a WP0, with the corresponding objectives being achievable within the 36 months of the project: WP1 Design, optimisation and production of the early test; aim: neuroaptamer prototypes, neuro-strips, neuro-magnetic beads, validation of packaging and sterilization process, and stabilised and validated supports. WP2 Alzheimer Diagnostic: Tau-181 and -231 markers; aim: choice of the marker candidate and the prototype to be tested in a multiplex trial. WP3 Dementia diagnostic and Lewy bodies: -synuclein marker; aim: development and validation of a suitable assay for -synuclein oligomers. WP4 Creutzfeldt-Jakob: PRION; aim: validation of aptamers, neurostrips and i-PCR. WP5 Therapeutic follow-up; aim: biological markers for future therapeutic follow-up validation WP6 Integrative section and fundamental knowledge derived from the other WPs; aim: validation of the multiplex assays systems. WP7 Accompaniment and regulatory follow-up. The work will be carried out by a consortium made up of 12 partners, coming from 6 European member-states. A complementary expertise and a multidisciplinary partnership of high quality has been gathered with academics, research centres, 1 technology transfer center, 2 hospitals, 2 industrial SMEs and 1 SME expert in regulatory aspects.

PERSONS (12/12)

RELATED NAVIGATION AREA(S) (3/3)